-
Mashup Score: 1
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4Ibrutinib Combined with Bortezomib Shows ‘Durable Efficacy’ in MCL - 6 month(s) ago
Ibrutinib combined with bortezomib showed “durable efficacy” and safety in patients with relapsed or refractory mantle cell lymphoma (MCL), according to a study published in eClinicalMedicine. The phase I/II trial, led by Urban Novak, MD, University Hospital of Bern in Switzerland, established the recommended phase II dose of ibrutinib combined with bortezomib and assessed its efficacy in patients with relapsed or refractory MCL. The study included ibrutinib-naïve and bortez omib-naïve patients with
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 4Brexu-cel Has ‘Substantial’ Benefit Over SOC in Relapsed or Refractory MCL Post-BTKi Therapy - 6 month(s) ago
Home > Mantle Cell Lymphoma > Brexu-cel Has ‘Substantial’ Benefit Over SOC in Relapsed or Refractory MCL Post-BTKi Therapy Researchers demonstrated a “substantial treatment benefit” in an indirect treatment comparison of brexucabtagene autoleucel (brexu-cel) with the standard of care in patients with relapsed or refractory mantle cell lymphoma (MCL) after Bruton tyrosine kinase inhibitor (BTKi) exposure, according to a study published in Leukemia and Lymphoma. The study, led by Georg Hess, MD, of the
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 0Addition of Venetoclax to Lenalidomide and Rituximab Therapy for Patients With Previously Untreated MCL - 7 month(s) ago
Kami J. Maddocks, MD, discusses results from a single-arm study on the addition of venetoclax to a lenalidomide and rituximab regimen for patients with previously untreated mantle cell lymphoma.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In this video, Kami J Maddocks, MD, discusses the results of a multicenter single-arm study that explored the addition of #venetoclax to #lenalidomide and #rituximab treatment for patients with previously untreated #MCL. Learn more: https://t.co/sqXKHEqdHY @kmaddmd #MedTwitter https://t.co/bYfGsyhWKm
-
-
Mashup Score: 0Exploring the Design of the ECOG-ACRIN E1411 Trial in MCL - 7 month(s) ago
Mitchell Smith, MD, PhD, discusses the ECOG-ACRIN E1411 trial among patients with previously untreated mantle cell lymphoma.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Allogeneic Stem Cell Transplantation Demonstrates Lasting Remissions Among Patients With MCL, Including With TP53 Mutations - 7 month(s) ago
Allogeneic stem cell transplantation demonstrated long-term remissions among patients with mantle cell lymphoma, including patients with TP53-mutated disease, according to an extended follow-up study.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 4Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma - 7 month(s) ago
The SCHOLAR-2 retrospective study highlighted poor overall survival (OS) with standard of care (SOC) regimens among patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) who failed a c…
Source: www.tandfonline.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Full article: Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma https://t.co/8dJRPL9B8S
-
-
Mashup Score: 0
At the 2023 Society of Hematologic Oncology Annual Meeting, Michael Wang, MD, reviews the latest research and treatment advances for patients with mantle cell lymphoma.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Prognostic Value of CAR-HEMATOTOX Score for Treatment Outcomes of Patients With R/R MCL Undergoing CAR T-Cell Therapy - 7 month(s) ago
CAR-HEMATOTOX scores predicted treatment outcomes and toxicity risks among patients with R/R MCL treated with CAR T-cell therapy, according to a multicenter observational study.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Pirtobrutinib Demonstrates Durable Efficacy and Safety Among Patients With Covalent BTK Inhibitor Pretreated R/R MCL - 7 month(s) ago
Kami J. Maddocks, MD, analyzes the updated results of the BRUIN trial on the efficacy and safety of pirtobrutinib among patients with high-risk heavily pretreated R/R mantle cell lymphoma with prior covalent BTK inhibitor therapy.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Relapsed/refractory #MCL has a poor prognosis with no established standard treatment, particularly for those not responding to Bruton tyrosine kinase inhibitors. To provide updated survival data, a comprehensive retrospective review was conducted. https://t.co/JHgT2Wk9wS https://t.co/gXG7cT8IxK